Prilenia
Company Details
Status: Private
Employees: 11-50
Location:
Boston, Massachusetts, United States
Type:
sample
Technology:
sample
About: Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders.
Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.
Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial.
The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018.
The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Prilenia | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.